With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class rare disease drug DIAG723. The Massachusetts-based biotech, which develops ...

High numbers of regulatory T cells (red) — seen here interacting with antigen-presenting cells (blue) — are usually associated with poorer outcomes in cancer. A new MSK study, however, found that a ...

Solve Intelligence, the AI platform for the $200B+ patent industry, has raised $40M in Series B funding and is launching a new product for generating patent claim charts. Solve’s Series B comes just ...

The new round, which follows a $12 million Series A earlier this year, includes participation from Thomson Reuters and the founder of Quinn Emanuel’s IP litigation practice. Solve Intelligence ...

An engineer for New York Times Games has been trying to teach artificial intelligence to understand wordplay more like a human. By Shafik Quoraishee Shafik Quoraishee is a machine-learning engineer ...

In “Straight Talk with Rick and Jal,” Harvard University’s Jal Mehta and I examine the reforms and enthusiasms that permeate education. In a field full of buzzwords, our goal is simple: Tell the truth ...

In “Straight Talk with Rick and Jal,” Harvard University’s Jal Mehta and I examine the reforms and enthusiasms that permeate education. In a field full of buzzwords, our goal is simple: Tell the truth ...

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts. Solve Therapeutics’ ...

Funding round was led by Yosemite, with participation from new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, and all existing investors Solve ...

On Tuesday, November 4, Zohran Mamdani clinched the election for mayor of New York City, capturing just over 50 percent of the vote in a four-way race. Mamdani, a member of the New York State Assembly ...